SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (9788)10/21/1997 12:16:00 AM
From: Henry Niman  Read Replies (2) of 32384
 
<<When they say "exclusive rights to LGND's metabolic disease technology to
develop more advanced diabetes, cardiovascular and related therapies" (obeisty,
others?), does this include ALL LGND's present compounds, ALL the compounds
they will get from the ALRI deal, and ALL future compounds they will develop which
target RXRs and PPARs? We were concerned about this since the first sentence of the
first paragraph under "Specifics of Collaboration" reads, "LLY will receive worldwide,
exclusive rights to LGND's compounds and technology associated with the Retinoid X
Receptor." The first sentence of the second paragraph reads, "Ligand will also receive
worldwide exclusive rights in certain areas to LGND's PPAR technology." Seems like
the RXR rights are more comprehensive than the PPAR rights. But it appears they are
giving LLY basically all the compounds (for RXR work, in any case) that LGND is
receiving from the ALRI deal, That seems like a lot to give away for what they are
getting, no?>>

ALRI is a R&D shell for retinoids and rexinoids. The LLY deal targets rexinoids and their applications for metabolic diseases. LGND has also developed PPARs. PPAR alpha is involved in energy metabolism (obesity and possibly cardiovascular disease). PPAR gamma is involved with type II diabetes (its activated by TZDs like Rezulin). LGND is getting a partner to develop these compounds for these indications.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News